MDXHealth (OTCMKTS:MXDHF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered in Herstal, Belgium. “
MDXHealth (MXDHF) opened at $4.30 on Wednesday. MDXHealth has a 52 week low of $3.80 and a 52 week high of $6.15.
MDxHealth SA, a molecular diagnostics company, develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients in Belgium and internationally. The companys tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MDXHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDXHealth and related companies with MarketBeat.com's FREE daily email newsletter.